相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 2 randomized trial of the 100 pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data
S-C Tang et al.
CANCER RESEARCH (2016)
Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
S. Adams et al.
CANCER RESEARCH (2016)
Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1 positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
H. S. Rugo et al.
CANCER RESEARCH (2016)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor trial
L. Y. Dirix et al.
CANCER RESEARCH (2016)
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Rita Nanda et al.
CANCER RESEARCH (2015)
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer
Leisha A. Emens et al.
CANCER RESEARCH (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab
Xiao Ni et al.
ONCOIMMUNOLOGY (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
Andrew T. Vaughan et al.
BLOOD (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Teemu T. Junttila et al.
CANCER RESEARCH (2014)
Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Yvonne Saenger et al.
CLINICAL CANCER RESEARCH (2014)
Bispecific antibody platforms for cancer immunotherapy
Roeland Lameris et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines
Elham Mohit et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - Impact of effector cells
Shan Chung et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
Michael A Postow et al.
Journal of Translational Medicine (2014)
Harnessing the immune system for the treatment of breast cancer
Xinguo Jiang
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
M. T. Isla Larrain et al.
TUMOR BIOLOGY (2014)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem H. Soliman et al.
ONCOTARGET (2014)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
Gang Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Myeloid-derived suppressor cells in breast cancer
Joseph Markowitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The role of intratumoral and systemic IL-6 in breast cancer
Christine Dethlefsen et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
Yan Ge et al.
CANCER LETTERS (2013)
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Xiaoqiang Tang
CANCER LETTERS (2013)
Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
Zachary C. Hartman et al.
CANCER RESEARCH (2013)
Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2-Overexpressing Metastatic Breast Cancer
Yuan Huang et al.
CURRENT DRUG TARGETS (2013)
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Baris Boyraz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
The role of tumor-associated macrophages in breast cancer progression
Elias Obeid et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Jinpu Yu et al.
JOURNAL OF IMMUNOLOGY (2013)
Interleukin-8 in Breast Cancer Progression
Natasa Todorovic-Rakovic et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer
Michael S. Hwang et al.
PLOS ONE (2013)
Hydrazinocurcumin Encapsuled Nanoparticles Re-Educate Tumor-Associated Macrophages and Exhibit Anti-Tumor Effects on Breast Cancer Following STAT3 Suppression (Publication with Expression of Concern. See vol. 14, 2019)
Xiwen Zhang et al.
PLOS ONE (2013)
Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
Jian Yang et al.
STEM CELLS (2013)
Introducing the society for immunotherapy of cancer's new journal: journal for immunoTherapy of cancer
Pedro J. Romero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Advances in bispecific biotherapeutics for the treatment of cancer
Chad May et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
A. J. Montero et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Dual HER2-targeted approaches in HER2-positive breast cancer
Eugene R. Ahn et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
R. Y. Tsang et al.
BRITISH JOURNAL OF CANCER (2012)
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Elizabeth A. Mittendorf et al.
CANCER (2012)
JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
Adrian Britschgi et al.
CANCER CELL (2012)
A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells
Archana Thakur et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine
T. J. Vreeland et al.
CANCER RESEARCH (2012)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures
Guozhu Xie et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tumour-infiltrating macrophages and clinical outcome in breast cancer
S. M. A. Mahmoud et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
The GP2 peptide: A HER2/neu-based breast cancer vaccine
Kevin S. Clive et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Jeffrey Schlom
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
Vivian L. Weiss et al.
PLOS ONE (2012)
Tumor Associated Macrophage X Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer
Jingxian Ding et al.
PLOS ONE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
Andrew J. Rech et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Differential macrophage programming in the tumor microenvironment
Brian Ruffell et al.
TRENDS IN IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome
Michael J. Campbell et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2011)
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
Gabriele Schaefer et al.
CANCER CELL (2011)
MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells
Shinji K. Oyama et al.
CANCER RESEARCH (2011)
An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence
D. F. Hale et al.
CANCER RESEARCH (2011)
Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
Purevdorj B. Olkhanud et al.
CANCER RESEARCH (2011)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
Scott K. Pruitt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
AE37: a novel T-cell-eliciting vaccine for breast cancer
Alan K. Sears et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis
Catherine E. Steding et al.
IMMUNOLOGY (2011)
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
Damya Laoui et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Hasan Korkaya et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells
Jingyan Sun et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2011)
Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
Wenjin Yin et al.
PLOS ONE (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeted therapy in breast cancer: what's new?
Lei Fang et al.
SWISS MEDICAL WEEKLY (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R. West et al.
BREAST CANCER RESEARCH (2011)
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
Ursula Wiedermann et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
Mark G. Carmichael et al.
CANCER (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Antiestrogens Induce Transforming Growth Factor β-Mediated Immunosuppression in Breast Cancer
Christian M. Joffroy et al.
CANCER RESEARCH (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
Jeremy D. Gates et al.
VACCINE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Arginase: an emerging key player in the mammalian immune system
Markus Munder
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
IDO inhibits T-cell function through suppressing Vav1 expression and activation
Runmei Li et al.
CANCER BIOLOGY & THERAPY (2009)
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
Johanna K. Morales et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Michael Jaeger et al.
CANCER RESEARCH (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
Michael Gobert et al.
CANCER RESEARCH (2009)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
Dimitrios Iliopoulos et al.
CELL (2009)
Cell Death Mechanisms Induced by Cytotoxic Lymphocytes
L. Chavez-Galan et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2009)
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Linda C. Benavides et al.
CLINICAL CANCER RESEARCH (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Pravin T. P. Kaumaya et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
M. K. Robinson et al.
BRITISH JOURNAL OF CANCER (2008)
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence - From US Military Cancer Institute clinical trials group study I-01 and I-02
Jarrod P. Holmes et al.
CANCER (2008)
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients:: US military cancer institute clinical trials group study I-01 and I-02
George E. Peoples et al.
CLINICAL CANCER RESEARCH (2008)
Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine
Jarrod P. Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy
Madhuri Kakarala et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target
Sandra D. Bohling et al.
MODERN PATHOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
Nectaria N. Sotiriadou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
Matthew T. Hueman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
Anita E. M. Dirkx et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine
Matthew T. Hueman et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Tumor antigen expression in melanoma varies according to antigen and stage
C Barrow et al.
CLINICAL CANCER RESEARCH (2006)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease
P Sinha et al.
JOURNAL OF IMMUNOLOGY (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses
NK Dakappagari et al.
JOURNAL OF IMMUNOLOGY (2003)
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
R Salgado et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
